Biomarker evaluation in the randomized, double-blind, placebo-controlled, Phase IIIb ATLAS Trial, comparing bevacizumab (B) therapy with or without erlotinib (E), after completion of chemotherapy with B for the treatment of locally-advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC)

被引：12
|
作者：
Johnson, B. [1 ]
Miller, V. [2 ]
Amler, L. [3 ]
Stern, H. [3 ]
Soh, C. [3 ]
O'Connor, P. [3 ]
Kabbinavar, F. [4 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Mem Sloan Kettering Canc Ctr, New York, NY USA
[3] Genentech Inc, San Francisco, CA 94080 USA
[4] Univ Calif Los Angeles, Los Angeles, CA USA
来源：
EJC SUPPLEMENTS | 2009年 / 7卷 / 03期
关键词：
D O I：
10.1016/S1359-6349(09)72037-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：5 / 6
页数：2
相关论文
共 50 条
  • [21] PACIFIC: A Double-Blind, Placebo-Controlled Phase 3 Study of Durvalumab as Consolidation Therapy After Chemoradiation in Patients with Locally Advanced, Unresectable Non-Small Cell Lung Cancer
    Antonia, S. J.
    Villegas, A.
    Daniel, D.
    Baz, D. Vincente
    Murakami, S.
    Hui, R.
    Yokoi, T.
    Chiappori, A.
    Lee, K. H.
    de Wit, M.
    Cho, B. C.
    Bourhaba, M.
    Quantin, X.
    Tokito, T.
    Mekhail, T.
    Planchard, D.
    Jiang, H.
    Huang, Y.
    Dennis, P. A.
    Ozguroglu, M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 99 (05): : 1314 - 1315
  • [22] First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial
    Lee, Siow Ming
    Khan, Iftekhar
    Upadhyay, Sunil
    Lewanski, Conrad
    Falk, Stephen
    Skailes, Geraldine
    Marshall, Ernie
    Woll, Penella J.
    Hatton, Matthew
    Lal, Rohit
    Jones, Richard
    Toy, Elizabeth
    Chao, David
    Middleton, Gary
    Bulley, Sue
    Ngai, Yenting
    Rudd, Robin
    Hackshaw, Allan
    Boshoff, Chris
    LANCET ONCOLOGY, 2012, 13 (11): : 1161 - 1170
  • [23] The efficacy and safety of TQ-B2450 alone/with anlotinib in previously treated advanced non-small cell lung cancer (NSCLC): A multicenter, randomized, double-blind, placebo-controlled clinical trial
    Han, B.
    Li, K.
    Wang, Q.
    Cheng, Y.
    Yang, L.
    Li, Y.
    ANNALS OF ONCOLOGY, 2021, 32 : S1429 - S1429
  • [24] A phase III randomised, double blind, placebo controlled trial of gemcitabine/carboplatin with or without thalidomide in advanced non-small cell lung cancer (NSCLC)
    Lee Siow-Ming
    Woll, Penella J.
    Rudd, Robin M.
    Gower, Nicole H.
    Ottensmeier, Christian H.
    Ali, Kulsam
    Spiro, Stephen G.
    Hackshaw, Allan
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S359 - S359
  • [25] A randomized phase II study comparing erlotinib with or without bevacizumab in patients with advanced non-small cell lung cancer (NSCLC) with EGFR mutation.
    Lee, Youngjoo
    Kim, Hye Ryun
    Hong, Min Hee
    Lee, Ki Hyeong
    Park, Keon Uk
    Lee, Geon Kook
    Kim, Hyae Young
    Lee, Soo-Hyun
    Lim, Kun Young
    Yoon, Sung Jin
    Cho, Byoung Chul
    Han, Ji-Youn
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [26] Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial of paclitaxel (Pac) and carboplatin (C) combined with erlotinib (E) or placebo in patients with advanced non-small cell lung cancer(NSCLC).
    Tran, HT
    Zinner, R
    Blumenschein, GR
    Oh, YW
    Papadimitrakopoulou, VA
    Kim, ES
    Lu, C
    Malik, M
    Lum, B
    Herbst, RS
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 139S - 139S
  • [27] Randomized, Double-Blind, Placebo-Controlled Phase II Study of Single-Agent Oral Talactoferrin in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer That Progressed After Chemotherapy
    Parikh, Purvish M.
    Vaid, Ashok
    Advani, Suresh H.
    Digumarti, Raghunadharao
    Madhavan, Jayaprakash
    Nag, Shona
    Bapna, Ajay
    Sekhon, Jagdev S.
    Patil, Shekhar
    Ismail, Preeti M.
    Wang, Yenyun
    Varadhachary, Atul
    Zhu, Junming
    Malik, Rajesh
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (31) : 4129 - 4136
  • [28] Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC)
    Tran, Hai T.
    Zinner, Ralph G.
    Blumenschein, George R., Jr.
    Oh, Yun W.
    Papadimitrakopoulou, Vassiliki A.
    Kim, Edward S.
    Lu, Charles
    Malik, Mubashira
    Lum, Bert L.
    Herbst, Roy S.
    INVESTIGATIONAL NEW DRUGS, 2011, 29 (03) : 499 - 505
  • [29] Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC)
    Hai T. Tran
    Ralph G. Zinner
    George R. Blumenschein
    Yun W. Oh
    Vassiliki A. Papadimitrakopoulou
    Edward S. Kim
    Charles Lu
    Mubashira Malik
    Bert L. Lum
    Roy S. Herbst
    Investigational New Drugs, 2011, 29 : 499 - 505
  • [30] Vitamin D Supplementation and Survival of Patients with Non-small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial
    Akiba, Tadashi
    Morikawa, Toshiaki
    Odaka, Makoto
    Nakada, Takeo
    Kamiya, Noriki
    Yamashita, Makoto
    Yabe, Mitsuo
    Inagaki, Takuya
    Asano, Hisatoshi
    Mori, Shohei
    Tsukamoto, Yo
    Urashima, Mitsuyoshi
    CLINICAL CANCER RESEARCH, 2018, 24 (17) : 4089 - 4097
12345